Recent Updates
Recently added Catalysts

gevokizumab

Phase 2

Acne Vulgaris | Small molecule | Dermatology |XOMA Royalty Corporation|Last Updated: Mar 4, 2014

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment127
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01498874Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne VulgarisPHASE2 COMPLETED 127 — — Dec 1, 2011Jun 1, 2013Mar 4, 201419 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
The mean absolute change from baseline in inflammatory facial lesion count at Day 84
Baseline and Day 84
Secondary Endpoints
The proportion of subjects with a successful treatment outcome at Day 84
Baseline and Day 84
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
PlaceboPLACEBO_COMPARATOR -
low dose gevokizumabEXPERIMENTAL -
high dose gevokizumabEXPERIMENTAL -
Interventions
NameTypeDescription
PlaceboDRUGSterile solution administered subcutaneously on Day 0, Day 28, and Day 56
gevokizumabDRUGSterile solution administered subcutaneously on Day 0, Day 28, and Day 56
Unlock Study Design Details
Eligibility Criteria
Age Range17 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites19

Inclusion Criteria: * Diagnosis of moderate to severe acne vulgaris * Acne vulgaris unresponsive to oral antibiotics * Willingness to maintain current habits for facial cleaning, shaving, and application of cosmetics through the end of the study Exclusion Criteria: * Use of medications or treatme...

Countries:United States
Unlock Eligibility Criteria